APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Montelukast API

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Montelukast API Market Outlook and Growth Opportunities 2026

Report ID 174014230431 December 2025194 pages

Choose your research edition.

Industry ResearchMontelukast API Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Montelukast API Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Montelukast API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Montelukast API Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Montelukast API Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Montelukast API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Montelukast API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Montelukast API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Montelukast API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Montelukast API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Montelukast API market include Merck, Mylan, Teva Pharmaceutical Industries, Sun Pharma, Sanyo Chemical Industries, Morepen Laboratories, Intas Pharmaceuticals, Delmar Chemicals and Cipla, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Montelukast API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Montelukast API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Montelukast API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Montelukast API market size, projected growth trends, production technologies, key applications, and end-use industries.

Montelukast API Segment by Company

Merck

Mylan

Teva Pharmaceutical Industries

Sun Pharma

Sanyo Chemical Industries

Morepen Laboratories

Intas Pharmaceuticals

Delmar Chemicals

Cipla

Apotex

Montelukast API Segment by Type

Chewable Tablet

Oral Solution

Tablet

Montelukast API Segment by Application

Bronchospasm

Urticaria

Asthma

Allergic Rhinitis

Others

Montelukast API Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Montelukast API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Montelukast API market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Montelukast API significant trends, drivers, influence factors in global and regions.

6. To analyze Montelukast API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Montelukast API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Montelukast API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Montelukast API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Montelukast API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Montelukast API industry.

Chapter 3: Detailed analysis of Montelukast API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Montelukast API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Montelukast API in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Montelukast API Industry Trends Table 2. Montelukast API Industry Drivers Table 3. Montelukast API Industry Opportunities and Challenges Table 4. Montelukast API Industry Restraints Table 5. Global Montelukast API Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Montelukast API Revenue Share by Company (2021-2026) Table 7. Global Montelukast API Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Montelukast API Sales Volume Share by Company (2021-2026) Table 9. Global Montelukast API Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Montelukast API Company Ranking, (2024-2026) & (USD Million) Table 11. Global Montelukast API Key Company Manufacturing Base & Headquarters Table 12. Global Montelukast API Company, Product Type & Application Table 13. Global Montelukast API Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Montelukast API by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Chewable Tablet Table 18. Significant Companies of Oral Solution Table 19. Significant Companies of Tablet Table 20. Global Montelukast API Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Montelukast API Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Montelukast API Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Montelukast API Sales Volume Share by Type (2021-2026) Table 24. Global Montelukast API Sales Volume Share by Type (2027-2032) Table 25. Global Montelukast API Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Montelukast API Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Montelukast API Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Montelukast API Sales Value Share by Type (2021-2026) Table 29. Global Montelukast API Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Bronchospasm Table 31. Significant Companies of Urticaria Table 32. Significant Companies of Asthma Table 33. Significant Companies of Allergic Rhinitis Table 34. Significant Companies of Others Table 35. Global Montelukast API Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Montelukast API Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Montelukast API Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Montelukast API Sales Volume Share by Application (2021-2026) Table 39. Global Montelukast API Sales Volume Share by Application (2027-2032) Table 40. Global Montelukast API Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Montelukast API Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Montelukast API Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Montelukast API Sales Value Share by Application (2021-2026) Table 44. Global Montelukast API Sales Value Share by Application (2027-2032) Table 45. Global Montelukast API Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Montelukast API Sales by Region (2021-2026) & (K Units) Table 47. Global Montelukast API Sales Market Share by Region (2021-2026) Table 48. Global Montelukast API Sales by Region (2027-2032) & (K Units) Table 49. Global Montelukast API Sales Market Share by Region (2027-2032) Table 50. Global Montelukast API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Montelukast API Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Montelukast API Sales Value Share by Region (2021-2026) Table 53. Global Montelukast API Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Montelukast API Sales Value Share by Region (2027-2032) Table 55. Global Montelukast API Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Montelukast API Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Montelukast API Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Montelukast API Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Montelukast API Sales by Country (2021-2026) & (K Units) Table 60. Global Montelukast API Sales Market Share by Country (2021-2026) Table 61. Global Montelukast API Sales by Country (2027-2032) & (K Units) Table 62. Global Montelukast API Sales Market Share by Country (2027-2032) Table 63. Global Montelukast API Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Montelukast API Sales Value Market Share by Country (2021-2026) Table 65. Global Montelukast API Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Montelukast API Sales Value Market Share by Country (2027-2032) Table 67. Merck Company Information Table 68. Merck Business Overview Table 69. Merck Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Merck Montelukast API Product Portfolio Table 71. Merck Recent Development Table 72. Mylan Company Information Table 73. Mylan Business Overview Table 74. Mylan Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Mylan Montelukast API Product Portfolio Table 76. Mylan Recent Development Table 77. Teva Pharmaceutical Industries Company Information Table 78. Teva Pharmaceutical Industries Business Overview Table 79. Teva Pharmaceutical Industries Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Teva Pharmaceutical Industries Montelukast API Product Portfolio Table 81. Teva Pharmaceutical Industries Recent Development Table 82. Sun Pharma Company Information Table 83. Sun Pharma Business Overview Table 84. Sun Pharma Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Sun Pharma Montelukast API Product Portfolio Table 86. Sun Pharma Recent Development Table 87. Sanyo Chemical Industries Company Information Table 88. Sanyo Chemical Industries Business Overview Table 89. Sanyo Chemical Industries Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Sanyo Chemical Industries Montelukast API Product Portfolio Table 91. Sanyo Chemical Industries Recent Development Table 92. Morepen Laboratories Company Information Table 93. Morepen Laboratories Business Overview Table 94. Morepen Laboratories Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Morepen Laboratories Montelukast API Product Portfolio Table 96. Morepen Laboratories Recent Development Table 97. Intas Pharmaceuticals Company Information Table 98. Intas Pharmaceuticals Business Overview Table 99. Intas Pharmaceuticals Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Intas Pharmaceuticals Montelukast API Product Portfolio Table 101. Intas Pharmaceuticals Recent Development Table 102. Delmar Chemicals Company Information Table 103. Delmar Chemicals Business Overview Table 104. Delmar Chemicals Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Delmar Chemicals Montelukast API Product Portfolio Table 106. Delmar Chemicals Recent Development Table 107. Cipla Company Information Table 108. Cipla Business Overview Table 109. Cipla Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Cipla Montelukast API Product Portfolio Table 111. Cipla Recent Development Table 112. Apotex Company Information Table 113. Apotex Business Overview Table 114. Apotex Montelukast API Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Apotex Montelukast API Product Portfolio Table 116. Apotex Recent Development Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Montelukast API Distributors List Table 120. Montelukast API Customers List Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Montelukast API Product Image Figure 2. Global Montelukast API Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Montelukast API Sales Value (2021-2032) & (US$ Million) Figure 4. Global Montelukast API Sales (2021-2032) & (K Units) Figure 5. Global Montelukast API Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Montelukast API Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Chewable Tablet Image Figure 10. Oral Solution Image Figure 11. Tablet Image Figure 12. Global Montelukast API Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Montelukast API Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Montelukast API Sales Volume Share by Type (2021-2032) Figure 15. Global Montelukast API Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Montelukast API Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Montelukast API Sales Value Share by Type (2021-2032) Figure 18. Bronchospasm Image Figure 19. Urticaria Image Figure 20. Asthma Image Figure 21. Allergic Rhinitis Image Figure 22. Others Image Figure 23. Global Montelukast API Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Montelukast API Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Montelukast API Sales Volume Share by Application (2021-2032) Figure 26. Global Montelukast API Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Montelukast API Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Montelukast API Sales Value Share by Application (2021-2032) Figure 29. Global Montelukast API Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Montelukast API Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Montelukast API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Montelukast API Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Montelukast API Sales Value (2021-2032) & (US$ Million) Figure 34. North America Montelukast API Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Montelukast API Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Montelukast API Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Montelukast API Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Montelukast API Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Montelukast API Sales Value (2021-2032) & (US$ Million) Figure 40. South America Montelukast API Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Montelukast API Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Montelukast API Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Montelukast API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Montelukast API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Montelukast API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Montelukast API Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Montelukast API Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Chewable Tablet
  • Oral Solution
  • Tablet
Applications
  • Bronchospasm
  • Urticaria
  • Asthma
  • Allergic Rhinitis
  • Others
Companies covered
  • Merck
  • Mylan
  • Teva Pharmaceutical Industries
  • Sun Pharma
  • Sanyo Chemical Industries
  • Morepen Laboratories
  • Intas Pharmaceuticals
  • Delmar Chemicals
  • Cipla
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Montelukast API Sales Value (2021-2032)
  4. 1.2.2 Global Montelukast API Sales Volume (2021-2032)
  5. 1.2.3 Global Montelukast API Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Montelukast API Market Dynamics
  1. 2.1 Montelukast API Industry Trends
  2. 2.2 Montelukast API Industry Drivers
  3. 2.3 Montelukast API Industry Opportunities and Challenges
  4. 2.4 Montelukast API Industry Restraints
3 Montelukast API Market by Company
  1. 3.1 Global Montelukast API Company Revenue Ranking in 2025
  2. 3.2 Global Montelukast API Revenue by Company (2021-2026)
  3. 3.3 Global Montelukast API Sales Volume by Company (2021-2026)
  4. 3.4 Global Montelukast API Average Price by Company (2021-2026)
  5. 3.5 Global Montelukast API Company Ranking (2024-2026)
  6. 3.6 Global Montelukast API Company Manufacturing Base and Headquarters
  7. 3.7 Global Montelukast API Company Product Type and Application
  8. 3.8 Global Montelukast API Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Montelukast API Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Montelukast API Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Montelukast API Market by Type
  1. 4.1 Montelukast API Type Introduction
  2. 4.1.1 Chewable Tablet
  3. 4.1.2 Oral Solution
  4. 4.1.3 Tablet
  5. 4.2 Global Montelukast API Sales Volume by Type
  6. 4.2.1 Global Montelukast API Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Montelukast API Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Montelukast API Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Montelukast API Sales Value by Type
  10. 4.3.1 Global Montelukast API Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Montelukast API Sales Value by Type (2021-2032)
  12. 4.3.3 Global Montelukast API Sales Value Share by Type (2021-2032)
5 Montelukast API Market by Application
  1. 5.1 Montelukast API Application Introduction
  2. 5.1.1 Bronchospasm
  3. 5.1.2 Urticaria
  4. 5.1.3 Asthma
  5. 5.1.4 Allergic Rhinitis
  6. 5.1.5 Others
  7. 5.2 Global Montelukast API Sales Volume by Application
  8. 5.2.1 Global Montelukast API Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Montelukast API Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Montelukast API Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Montelukast API Sales Value by Application
  12. 5.3.1 Global Montelukast API Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Montelukast API Sales Value by Application (2021-2032)
  14. 5.3.3 Global Montelukast API Sales Value Share by Application (2021-2032)
6 Montelukast API Regional Sales and Value Analysis
  1. 6.1 Global Montelukast API Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Montelukast API Sales by Region (2021-2032)
  3. 6.2.1 Global Montelukast API Sales by Region: 2021-2026
  4. 6.2.2 Global Montelukast API Sales by Region (2027-2032)
  5. 6.3 Global Montelukast API Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Montelukast API Sales Value by Region (2021-2032)
  7. 6.4.1 Global Montelukast API Sales Value by Region: 2021-2026
  8. 6.4.2 Global Montelukast API Sales Value by Region (2027-2032)
  9. 6.5 Global Montelukast API Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Montelukast API Sales Value (2021-2032)
  12. 6.6.2 North America Montelukast API Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Montelukast API Sales Value (2021-2032)
  15. 6.7.2 Europe Montelukast API Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Montelukast API Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Montelukast API Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Montelukast API Sales Value (2021-2032)
  21. 6.9.2 South America Montelukast API Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Montelukast API Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Montelukast API Sales Value Share by Country, 2025 VS 2032
7 Montelukast API Country-level Sales and Value Analysis
  1. 7.1 Global Montelukast API Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Montelukast API Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Montelukast API Sales by Country (2021-2032)
  4. 7.3.1 Global Montelukast API Sales by Country (2021-2026)
  5. 7.3.2 Global Montelukast API Sales by Country (2027-2032)
  6. 7.4 Global Montelukast API Sales Value by Country (2021-2032)
  7. 7.4.1 Global Montelukast API Sales Value by Country (2021-2026)
  8. 7.4.2 Global Montelukast API Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Montelukast API Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Montelukast API Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Montelukast API Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Montelukast API Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Montelukast API Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Montelukast API Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Montelukast API Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Montelukast API Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Montelukast API Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Montelukast API Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Montelukast API Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Montelukast API Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Montelukast API Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Montelukast API Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Montelukast API Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Montelukast API Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Montelukast API Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Montelukast API Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Montelukast API Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Montelukast API Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Montelukast API Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Montelukast API Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Montelukast API Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Montelukast API Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Montelukast API Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Montelukast API Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Montelukast API Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Montelukast API Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Montelukast API Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Montelukast API Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Montelukast API Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Montelukast API Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Montelukast API Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Montelukast API Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Montelukast API Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Montelukast API Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Montelukast API Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Montelukast API Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Montelukast API Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Montelukast API Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Montelukast API Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Montelukast API Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Montelukast API Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Montelukast API Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Montelukast API Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Montelukast API Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Montelukast API Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Montelukast API Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Montelukast API Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Montelukast API Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Montelukast API Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Montelukast API Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Montelukast API Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Montelukast API Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Montelukast API Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Montelukast API Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Montelukast API Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Montelukast API Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Montelukast API Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Montelukast API Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Montelukast API Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Montelukast API Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Montelukast API Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Montelukast API Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Montelukast API Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Montelukast API Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Montelukast API Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Montelukast API Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Montelukast API Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Montelukast API Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Montelukast API Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Montelukast API Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Montelukast API Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Montelukast API Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Montelukast API Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Montelukast API Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Montelukast API Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Montelukast API Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Montelukast API Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Montelukast API Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Montelukast API Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Montelukast API Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Montelukast API Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Montelukast API Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Montelukast API Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Montelukast API Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Mylan
  8. 8.2.1 Mylan Company Information
  9. 8.2.2 Mylan Business Overview
  10. 8.2.3 Mylan Montelukast API Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Mylan Montelukast API Product Portfolio
  12. 8.2.5 Mylan Recent Developments
  13. 8.3 Teva Pharmaceutical Industries
  14. 8.3.1 Teva Pharmaceutical Industries Company Information
  15. 8.3.2 Teva Pharmaceutical Industries Business Overview
  16. 8.3.3 Teva Pharmaceutical Industries Montelukast API Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Teva Pharmaceutical Industries Montelukast API Product Portfolio
  18. 8.3.5 Teva Pharmaceutical Industries Recent Developments
  19. 8.4 Sun Pharma
  20. 8.4.1 Sun Pharma Company Information
  21. 8.4.2 Sun Pharma Business Overview
  22. 8.4.3 Sun Pharma Montelukast API Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sun Pharma Montelukast API Product Portfolio
  24. 8.4.5 Sun Pharma Recent Developments
  25. 8.5 Sanyo Chemical Industries
  26. 8.5.1 Sanyo Chemical Industries Company Information
  27. 8.5.2 Sanyo Chemical Industries Business Overview
  28. 8.5.3 Sanyo Chemical Industries Montelukast API Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanyo Chemical Industries Montelukast API Product Portfolio
  30. 8.5.5 Sanyo Chemical Industries Recent Developments
  31. 8.6 Morepen Laboratories
  32. 8.6.1 Morepen Laboratories Company Information
  33. 8.6.2 Morepen Laboratories Business Overview
  34. 8.6.3 Morepen Laboratories Montelukast API Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Morepen Laboratories Montelukast API Product Portfolio
  36. 8.6.5 Morepen Laboratories Recent Developments
  37. 8.7 Intas Pharmaceuticals
  38. 8.7.1 Intas Pharmaceuticals Company Information
  39. 8.7.2 Intas Pharmaceuticals Business Overview
  40. 8.7.3 Intas Pharmaceuticals Montelukast API Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Intas Pharmaceuticals Montelukast API Product Portfolio
  42. 8.7.5 Intas Pharmaceuticals Recent Developments
  43. 8.8 Delmar Chemicals
  44. 8.8.1 Delmar Chemicals Company Information
  45. 8.8.2 Delmar Chemicals Business Overview
  46. 8.8.3 Delmar Chemicals Montelukast API Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Delmar Chemicals Montelukast API Product Portfolio
  48. 8.8.5 Delmar Chemicals Recent Developments
  49. 8.9 Cipla
  50. 8.9.1 Cipla Company Information
  51. 8.9.2 Cipla Business Overview
  52. 8.9.3 Cipla Montelukast API Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Cipla Montelukast API Product Portfolio
  54. 8.9.5 Cipla Recent Developments
  55. 8.10 Apotex
  56. 8.10.1 Apotex Company Information
  57. 8.10.2 Apotex Business Overview
  58. 8.10.3 Apotex Montelukast API Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Apotex Montelukast API Product Portfolio
  60. 8.10.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Montelukast API Value Chain Analysis
  2. 9.1.1 Montelukast API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Montelukast API Sales Mode & Process
  6. 9.2 Montelukast API Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Montelukast API Distributors
  9. 9.2.3 Montelukast API Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst